Uses and methods of drug conjugates in treating tumor diseases
A biologically active conjugate targeting Trop-2 with a specific compound formula enhances treatment efficacy for refractory cancers by reducing tumor volume and improving response rates in cancers like triple-negative breast cancer and gastric cancer, addressing the limitations of current ADC drugs.
Patent Information
- Application Number
- JP2025547979
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-07
- Filing Date
- 2024-02-22
- Publication Date
- 2026-02-27
AI Technical Summary
Current ADC drugs face challenges in pharmacokinetics and safety, leading to serious adverse reactions and suboptimal response rates for metastatic, recurrent, and refractory cancers, necessitating improved treatment methods that maximize efficacy and minimize toxicity.
A biologically active conjugate represented by a specific compound formula, combining a monoclonal antibody or its antigen-binding fragment with a biologically active molecular fragment, is used to target and treat unresectable locally advanced or metastatic solid tumors that have failed standard treatments, including first-line chemotherapy, radiation therapy, and targeted therapy.
The conjugate effectively reduces tumor volume and improves response rates in cancers such as triple-negative breast cancer, Her2-positive breast cancer, ovarian cancer, and gastric cancer, with minimal side effects, even in patients with primary endocrine resistance and multiple chemotherapy lines.
Smart Images
Figure 2026506975000001_ABST